Opus Genetics vs Palatin Technologies
IRD and PTN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IRD and PTN compare
Opus Genetics is the larger company, worth 30 times as much as Palatin Technologies ($331M against $11.1M).
Palatin Technologies scores higher on the StockData Score (6 against 5 for Opus Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IRD | PTN |
|---|---|---|
| Size and price | ||
| Market cap | $331M | $11.1M |
| Share price | $3.98 | $6.23 |
| Change, 1 year | 107% | −43.6% |
| Change, 5 years | 9.3% | −98.6% |
| Beta (5Y) | 0.97 | 0.77 |
| Employees | 27 | 25 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 4 | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 41.8× | – |
| P/B | 8.6× | 1.7× (better) |
| FCF yield | – | −122% |
| Fair value | $0.711 | – |
| Margin of safety | −460% | – |
| Growth | ||
| Revenue growth (TTM) | −45.9% | – |
| Profitability | ||
| Operating margin | −778% | – |
| Net margin | −1727% | – |
| Return on equity | −616% (better) | −878% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −217.5× (better) | −1288.8× |
| Current ratio | 9.65 (better) | 4.61 |
| Altman Z-score | −2.02 (better) | −75.61 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | −0.73% (better) | −152% |
| Shareholder yield | −0.73% (better) | −152% |
| Ownership | ||
| Held by institutions | 72.8% | 38.5% |
| Held by insiders | 37.6% | 20.6% |
| Insider net buying, 12 months | −$19.4M | −$9.5K (better) |
| Short interest, % of float | 20.9% | 20.9% |
Go deeper
- IRD stock overview
- IRD income statement
- IRD valuation and score
- PTN stock overview
- PTN income statement
- PTN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.